CYLD-Mediated Signaling and Diseases

Author(s): Bryan J. Mathis, Yimu Lai, Chen Qu, Joseph S. Janicki, Taixing Cui

Journal Name: Current Drug Targets

Volume 16 , Issue 4 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The conserved cylindromatosis (CYLD) codes for a deubiquitinating enzyme and is a crucial regulator of diverse cellular processes such as immune responses, inflammation, death, and proliferation. It directly regulates multiple key signaling cascades, such as the Nuclear Factor kappa B [NFkB] and the Mitogen-Activated Protein Kinase (MAPK) pathways, by its catalytic activity on polyubiquitinated key intermediates. Several lines of emerging evidence have linked CYLD to the pathogenesis of various maladies, including cancer, poor infection control, lung fibrosis, neural development, and now cardiovascular dysfunction. While CYLD-mediated signaling is cell type and stimuli specific, the activity of CYLD is tightly controlled by phosphorylation and other regulators such as Snail. This review explores a broad selection of current and past literature regarding CYLD’s expression, function and regulation with emerging reports on its role in cardiovascular disease.

Keywords: Cardiovascular, CYLD, cylindromatosis, deubiquitination, K63, MAPK, NF-kB.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [284 - 294]
Pages: 11
DOI: 10.2174/1389450115666141024152421
Price: $65

Article Metrics

PDF: 64